Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 10, 2011, Pages 2105-2114

  Khoury, Muin J ^a,b   Clauser, Steven B ^b   Freedman, Andrew N ^b   Gillanders, Elizabeth M ^b   Glasgow, Russ E ^b   Klein, William M P ^b   Schully, Sheri D ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIORAL SCIENCE; CANCER RESEARCH; COMPARATIVE EFFECTIVENESS; EPIDEMIOLOGICAL DATA; GENOMICS; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; HUMAN; INFORMATION SCIENCE; NEOPLASM; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; SOCIOLOGY; TRANSLATIONAL RESEARCH;

DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; GENETICS, POPULATION; GENOMICS; HISTORY, 21ST CENTURY; HUMANS; PREVENTIVE MEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80053515901     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0481     Document Type: Review

References (74)

1. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. New Engl J Med 2011;364:340-50.
2. Calzone K, Wattendorf D, Dunn BK. The application of genetics and genomics to cancer prevention. Sem Oncol 2010;37:407-18.
3. Varmus H. Ten years on- the human genome and medicine. New Engl J Med 2010;362:2028-9.
4. Lander ES. Initial impact of the sequencing of the human genome. Nature 2011;470:187-97.
5. Plon SE. Unifying cancer genetics. Genet Med 2011;13:203-4.
6. Ladanyi M, Hogendoom PCW. Cancer biology and genomics: translating discoveries, transforming pathology. J Pathol 2011;223: 99-101.
7. Stadler ZK, Vijai J, Thom P, Kirchhoff T, Hansen NA, Kauff ND, et al. Genomewide association studies of cancer predisposition. Hematol Oncol Clin North Am 2010;24:973-96.
8. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. New Engl J Med 2011;364:524-34.
9. Gwinn M, Grossniklaus DA, Yu W, Melillo S, Wulf A, Flome J, et al. Horizon scanning for new genomic tests. Genet Med 2011;13:161-5.
10. Friends of Cancer Research. Improving medical decisions through comparative effectiveness research: cancer as a case study. [cited 2011 Apr 5]. Available from: http://focr.org/files/CER-REPORT-FINAL.pdf.
11. Khoury MJ, Berg A, Coates RC, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. Health Affairs 2008;27:1600-11.
12. Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now. J Pathol 2011;223:318-26.
13. Swanton C, Caldas C. From genomic landscapes to personalized cancer management- is there a road map? Ann NY Acad Sci 2010;1210:34-44.
14. Phillips KA. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 2008;300:2542-4.
15. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665-74. (Pubitemid 350287151)
16. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Publ Health Genomics 2011;14:1-8.
17. Spitz M, Bondy ML. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis 2010;31:127-34.
18. Hartman M, Loy EY, Ku CS, Chia KS. Molecular epidemiology and its current use in cancer management. Lancet Oncol 2010;11:383-90.
19. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families chose more healthful behaviors? Ann Rev Publ Health 2010;31:89-103.
20. Condit CM. Public understandings of risks from gene-environment interaction in common diseases: implications for public communications. Public Health Genomics 2011;14:115-24.
21. Rabin BA, Glasgow RA, Kerner JF, Klump MP, Brownson RC. Dissemination and implementation research on community-based cancer prevention: a systematic review. Am J Prev Med 2010;38:443-56.
22. Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J. Comparative effectiveness research and genomic medicine: an evolving relationship for 21st century medicine. Genet Med 2009;11:707-11.
23. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
24. Stokols D, Hall KL, Taylor BK, Moser RP. The science of team science: overview of the field and introduction to the supplement. Am J Prev Med 2008;35 Suppl 2:77-89.
25. Milstein B, Homer J, Hirsch SM. Analyzing national health reform strategies with a dynamic simulation model. Am J Public Health 2010; 100:811-9.
26. Avorn J. In defense of pharmacoepidemiology: embracing the yin and the yang of drug research. N Engl J Med 2007;357:2219-21. (Pubitemid 350190751)
27. Atkins D. Creating and synthesizing evidence with decision makers in mind. Integrating evidence from clinical trials and other study designs. Med Care 2007;45:S16-22.
28. Mercer SM, DeVinney BJ, Fine LJ, Green LW. Study designs for effectiveness and translation research: identifying trade-offs. Am J Prev Med 2007:33:139-154.
29. Institute of Medicine. The learning healthcare system. Washington D. C.: National Academies Press; 2007.
30. Hirschhorn JN, Gajdos ZK. Genomewide association studies: results from the first few years and potential implications for clinical medicine. Ann Rev Med 2011:62:11-24.
31. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009;41:579-84.
32. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova O, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone-receptor negative breast cancer in the general population. Nat Genet 2010; 42:885-92.
33. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. New Engl J Med 2008;358:2585-93. (Pubitemid 351831359)
34. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg- Solomon RZ, Jacobs KB, et al. A genomewide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
35. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009;69:10-5.
36. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genomewide association study of lung cancer identifies a region of chromosome 15p15 associated with risk for adenocarcinoma. Am J Hum Genet 2009;85:679-91.
37. Tenesa A, Farrington SM, Prendergast JG, Walker M, Haq N, Barnetson RA, et al. Genomewide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008;40:631-40.
38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
39. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007;26:6577-92. (Pubitemid 47573679)
40. Wang G, Kelley RK. KRAS mutational analysis for colorectal cancer. PLoS Curr 2010;2. pii: RRN1175.
41. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Int Med 2011;154:37-49.
42. Brewer JK. Behavior genetics of the cancer/depression correlation: a look at the Ras oncogene family and the "cerebral diabetes paradigm". J Mol Neurosci 2008;35:307-22.
43. Morgan D, Sylvester H, Lucas FL, Miesfeldt S, et al. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 2009;8:277-87.
44. Thompson HS, Valdimardottir HB, Duteau-Buck C, Guevarra J, Bovbjerg DH, Richmond-Avellaneda C, et al. Psychosocial predictors of BRCA counseling and testing decision among urban African-American women. Cancer Epi Biom Prev 2002;11:1579-82.
45. Vos J, Gomez-Garcia E, Oosterwijk JC, Menko FH, Stoel RD, Van Asperen CJ, et al. Opening the psychological black box in genetic counseling: the psychological impact of DNA testing is predicted by the counselee's perception, the medical impact by the pathogenic or uninformative BRCA1/2 result. Psychooncology Epub2010 Nov 11.
46. Ramsey S, Blough D, McDermott C, Clarke L, Bennet R, Burke W, et al. Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior? Findings from a population-based study. Publ Health Genomics Epub2010 Jan 13.
47. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk reducing surgery in BRCA1 and BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304: 967-75.
48. Nutbeam D. The evolving concept of health literacy. Soc Sci Med 2008;67:2072-8.
49. O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan- Davey E, et al. Genetically decreased CYP2D6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 2004;13:422-8. (Pubitemid 39635932)
50. Kaphingst KA, LaChance CR, Condit CM. Beliefs about heritability of cancer and health information seeking and preventive behaviors. J Cancer Edu 2009;24:351-6.
51. Goodenberger M, Lindor NM. Lynch and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol Epub2011 Feb 5.
52. EGAPP: recommendation from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
53. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
54. Agency for Healthcare Research Quality. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. [cited 2011 Mar 8]. Available from: http://www.ahrq.gov/downloads/pub/evidence/pdf/hnpcc/hnpcc. pdf.
55. Mvundura M, Grosse SD, Hampel H, Palomaki GE. Cost effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed cases of colorectal cancer. Genet Med 2010;12:93-104.
56. Hadley DW, Ashida S, Jenkins JF, Martin JC, Kalzone KA, Kuhn NR, et al. Generation after generation: exploring the psychological impact of providing genetic services through a cascading approach. Genet Med 2010;12:808-15.
57. National Cancer Institute, Division of Cancer Control and Population Sciences, comparative effectiveness research in genomics and personalized medicine. [cited 2011 Mar 8]. Available from: http://cancercontrol.cancer.gov/ od/phg/research.asp?type=CER.
58. Kawamoto K, Lobach DF, Willard HF, Ginsburg GS. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med Inform Dec Mak 2009;9:17.
59. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review: a new method of systematic review designed for complex policy interventions. J Health Services Res and Policy 2005:10 (Suppl 1): S21-39.
60. Glasgow RE. What types of evidence are most needed to advance behavioral medicine? Annals Behav Med 2008;35:19-25.
61. Wilfert B, Swen J, Mulder H, Touw W, Maitland Van der Zee AH, Deneer V, et al. From evidence-based medicine to mechanism-based medicine: reviewing the role of pharmacogenetics. Int J Clin Pharmacol 2011;33:3-9.
62. EGAPP-evaluation of genomic applications in practice and prevention working group: methods of the EGAPP working group. Genet Med 2009;11:3-14. [cited 2011 Mar 8]. Available from: www.egappreviews.org.
63. Evaluation of genomic applications in practice and prevention working group: can tumor gene expression profiling improve outcomes in patients with breast cancer. Genet Med 2009;11:66-73.
64. Roth JA, Garrison LP Jr, Burke W, Ramsey SD, Carlsson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Publ Health Genom 2011;14:49-67.
65. Khoury MJ. Dealing with the evidence dilemma in genomics and personalized medicine. Clin Pharmacol Therap 2010;87:636-8.
66. President's Council of Advisors on Science and Technology. Priorities for personalized medicine 2008. [cited 2011 Mar 17]. Available from: http://www.whitehouse.gov/files/documents/ostp/PCAST/pcast-report-v2.pdf.
67. Institute of Medicine. The promises and challenges of improving detection and treatment. National Academies Press2007. [cited 2011 Mar 17]. Available from: http://www.iom.edu/Reports/2007/ Cancer-Biomarkers-The-Promises-and- Challenges-of-Improving-Detection-and-Treatment.aspx.
68. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Int Med 2009;151:203-5.
69. Khoury MJ, McBride CM, Schully SD, Ioannidis JP, Feero WG, Janssens AC, et al. The scientific foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009;11:559-67.
70. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, et al. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. JNCI 2010;102:1698-1705.
71. McBride CM, Bowen D, Brody LC, Condit CM, Croyle RT, Gwinn M, et al. Future health applications for genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med 2010;38:556-61.
72. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, et al. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics 2009;12:233-44.
73. Klesges LM, Estabrooks Pa, Glasgow RE, Dzewaltowki D. Beginning with the application in mind: Designing and planning health behavior change interventions to enhance dissemination. Ann Behav Med 2005;29:66S-75S.
74. National Cancer Institute: designing for dissemination. [cited 2011 Apr 4]. Available from: www.cancercontrol.cancer.gov/d4d/.